A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm
There is a lack of evidence on the clinical efficacy and safety of the recently released Chinese botulinum toxin serotype A (Prosigne) for the treatment of focal dystonias and hemifacial spasm. Determining a more precise role of Prosigne in the treatment of such conditions is of paramount importance...
Gespeichert in:
| Veröffentlicht in: | Clinical neuropharmacology 2007-01, Vol.30 (1), p.39-42 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 42 |
|---|---|
| container_issue | 1 |
| container_start_page | 39 |
| container_title | Clinical neuropharmacology |
| container_volume | 30 |
| creator | Rieder, Carlos R M Schestatsky, Pedro Socal, Mariana Peixoto Monte, Thaís Lampert Fricke, Daniele Costa, João Picon, Paulo Dornelles |
| description | There is a lack of evidence on the clinical efficacy and safety of the recently released Chinese botulinum toxin serotype A (Prosigne) for the treatment of focal dystonias and hemifacial spasm. Determining a more precise role of Prosigne in the treatment of such conditions is of paramount importance, because botulinum toxin type A treatments have a huge economic implication in health services, especially in developing countries. The aim of our study was to compare the efficacy and safety of Prosigne in the treatment of blepharospasm and hemifacial spasm in comparison to Botox. We performed a double-blind, randomized, crossover study enrolling 26 patients. There were no significant differences between Prosigne and Botox regarding subjective global improvement, response onset, efficacy duration, and incidence and severity of adverse events. Our results suggest that Prosigne and Botox are comparable with respect to efficacy and safety for the short-term treatment of blepharospasm and hemifacial spasm. |
| doi_str_mv | 10.1097/01.WNF.0000236771.77021.3C |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20491970</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20491970</sourcerecordid><originalsourceid>FETCH-LOGICAL-c373t-561c7098cf2e5d0f21fd01ce1f0225382b13511600156a2f3bb092465aa9c6b43</originalsourceid><addsrcrecordid>eNpFkMtOwzAQRb0A0VL4BWSxYEXDjJ3YNTtUUUCqYANiaTmJTY3yIk54fT2mVMKbsa7u3Jk5hJwiJAhKXgAmz_erBOJjXEiJiZTAMOHLPTIFLtg8EyKdkMMQXqNnoVJ1QCYomWRKLKbk84qW7ZhXdp5XvinPaW-asq39t43_om9DaN9tT8Mwll-0dbSLkn9pLI1qGAPN26H9pL6hnRm8bYZAP_ywoTGw25jo7UyoaYykG1t7ZwpvKroVj8i-M1Wwx7s6I0-r68fl7Xz9cHO3vFrPCy75ELfHQoJaFI7ZrATH0JWAhUUHjGV8wXLkGaIAwEwY5nieg2KpyIxRhchTPiNnf7lx87fRhkHXPhS2qkxj2zFoBqlCJSEaL_-M26t763TX-9r0XxpB_7LWgDqy1v-s9Za15svYfLKbMua1Lf9bd6D5D14rfqw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20491970</pqid></control><display><type>article</type><title>A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Rieder, Carlos R M ; Schestatsky, Pedro ; Socal, Mariana Peixoto ; Monte, Thaís Lampert ; Fricke, Daniele ; Costa, João ; Picon, Paulo Dornelles</creator><creatorcontrib>Rieder, Carlos R M ; Schestatsky, Pedro ; Socal, Mariana Peixoto ; Monte, Thaís Lampert ; Fricke, Daniele ; Costa, João ; Picon, Paulo Dornelles</creatorcontrib><description>There is a lack of evidence on the clinical efficacy and safety of the recently released Chinese botulinum toxin serotype A (Prosigne) for the treatment of focal dystonias and hemifacial spasm. Determining a more precise role of Prosigne in the treatment of such conditions is of paramount importance, because botulinum toxin type A treatments have a huge economic implication in health services, especially in developing countries. The aim of our study was to compare the efficacy and safety of Prosigne in the treatment of blepharospasm and hemifacial spasm in comparison to Botox. We performed a double-blind, randomized, crossover study enrolling 26 patients. There were no significant differences between Prosigne and Botox regarding subjective global improvement, response onset, efficacy duration, and incidence and severity of adverse events. Our results suggest that Prosigne and Botox are comparable with respect to efficacy and safety for the short-term treatment of blepharospasm and hemifacial spasm.</description><identifier>ISSN: 0362-5664</identifier><identifier>DOI: 10.1097/01.WNF.0000236771.77021.3C</identifier><identifier>PMID: 17272968</identifier><language>eng</language><publisher>United States</publisher><subject>Blepharospasm - drug therapy ; Botulinum Toxins, Type A - pharmacology ; Cross-Over Studies ; Double-Blind Method ; Drugs, Chinese Herbal - pharmacology ; Female ; Hemifacial Spasm - drug therapy ; Humans ; Male ; Middle Aged ; Treatment Outcome</subject><ispartof>Clinical neuropharmacology, 2007-01, Vol.30 (1), p.39-42</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c373t-561c7098cf2e5d0f21fd01ce1f0225382b13511600156a2f3bb092465aa9c6b43</citedby><cites>FETCH-LOGICAL-c373t-561c7098cf2e5d0f21fd01ce1f0225382b13511600156a2f3bb092465aa9c6b43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17272968$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rieder, Carlos R M</creatorcontrib><creatorcontrib>Schestatsky, Pedro</creatorcontrib><creatorcontrib>Socal, Mariana Peixoto</creatorcontrib><creatorcontrib>Monte, Thaís Lampert</creatorcontrib><creatorcontrib>Fricke, Daniele</creatorcontrib><creatorcontrib>Costa, João</creatorcontrib><creatorcontrib>Picon, Paulo Dornelles</creatorcontrib><title>A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm</title><title>Clinical neuropharmacology</title><addtitle>Clin Neuropharmacol</addtitle><description>There is a lack of evidence on the clinical efficacy and safety of the recently released Chinese botulinum toxin serotype A (Prosigne) for the treatment of focal dystonias and hemifacial spasm. Determining a more precise role of Prosigne in the treatment of such conditions is of paramount importance, because botulinum toxin type A treatments have a huge economic implication in health services, especially in developing countries. The aim of our study was to compare the efficacy and safety of Prosigne in the treatment of blepharospasm and hemifacial spasm in comparison to Botox. We performed a double-blind, randomized, crossover study enrolling 26 patients. There were no significant differences between Prosigne and Botox regarding subjective global improvement, response onset, efficacy duration, and incidence and severity of adverse events. Our results suggest that Prosigne and Botox are comparable with respect to efficacy and safety for the short-term treatment of blepharospasm and hemifacial spasm.</description><subject>Blepharospasm - drug therapy</subject><subject>Botulinum Toxins, Type A - pharmacology</subject><subject>Cross-Over Studies</subject><subject>Double-Blind Method</subject><subject>Drugs, Chinese Herbal - pharmacology</subject><subject>Female</subject><subject>Hemifacial Spasm - drug therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Treatment Outcome</subject><issn>0362-5664</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtOwzAQRb0A0VL4BWSxYEXDjJ3YNTtUUUCqYANiaTmJTY3yIk54fT2mVMKbsa7u3Jk5hJwiJAhKXgAmz_erBOJjXEiJiZTAMOHLPTIFLtg8EyKdkMMQXqNnoVJ1QCYomWRKLKbk84qW7ZhXdp5XvinPaW-asq39t43_om9DaN9tT8Mwll-0dbSLkn9pLI1qGAPN26H9pL6hnRm8bYZAP_ywoTGw25jo7UyoaYykG1t7ZwpvKroVj8i-M1Wwx7s6I0-r68fl7Xz9cHO3vFrPCy75ELfHQoJaFI7ZrATH0JWAhUUHjGV8wXLkGaIAwEwY5nieg2KpyIxRhchTPiNnf7lx87fRhkHXPhS2qkxj2zFoBqlCJSEaL_-M26t763TX-9r0XxpB_7LWgDqy1v-s9Za15svYfLKbMua1Lf9bd6D5D14rfqw</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Rieder, Carlos R M</creator><creator>Schestatsky, Pedro</creator><creator>Socal, Mariana Peixoto</creator><creator>Monte, Thaís Lampert</creator><creator>Fricke, Daniele</creator><creator>Costa, João</creator><creator>Picon, Paulo Dornelles</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>20070101</creationdate><title>A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm</title><author>Rieder, Carlos R M ; Schestatsky, Pedro ; Socal, Mariana Peixoto ; Monte, Thaís Lampert ; Fricke, Daniele ; Costa, João ; Picon, Paulo Dornelles</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c373t-561c7098cf2e5d0f21fd01ce1f0225382b13511600156a2f3bb092465aa9c6b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Blepharospasm - drug therapy</topic><topic>Botulinum Toxins, Type A - pharmacology</topic><topic>Cross-Over Studies</topic><topic>Double-Blind Method</topic><topic>Drugs, Chinese Herbal - pharmacology</topic><topic>Female</topic><topic>Hemifacial Spasm - drug therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rieder, Carlos R M</creatorcontrib><creatorcontrib>Schestatsky, Pedro</creatorcontrib><creatorcontrib>Socal, Mariana Peixoto</creatorcontrib><creatorcontrib>Monte, Thaís Lampert</creatorcontrib><creatorcontrib>Fricke, Daniele</creatorcontrib><creatorcontrib>Costa, João</creatorcontrib><creatorcontrib>Picon, Paulo Dornelles</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Clinical neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rieder, Carlos R M</au><au>Schestatsky, Pedro</au><au>Socal, Mariana Peixoto</au><au>Monte, Thaís Lampert</au><au>Fricke, Daniele</au><au>Costa, João</au><au>Picon, Paulo Dornelles</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm</atitle><jtitle>Clinical neuropharmacology</jtitle><addtitle>Clin Neuropharmacol</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>30</volume><issue>1</issue><spage>39</spage><epage>42</epage><pages>39-42</pages><issn>0362-5664</issn><abstract>There is a lack of evidence on the clinical efficacy and safety of the recently released Chinese botulinum toxin serotype A (Prosigne) for the treatment of focal dystonias and hemifacial spasm. Determining a more precise role of Prosigne in the treatment of such conditions is of paramount importance, because botulinum toxin type A treatments have a huge economic implication in health services, especially in developing countries. The aim of our study was to compare the efficacy and safety of Prosigne in the treatment of blepharospasm and hemifacial spasm in comparison to Botox. We performed a double-blind, randomized, crossover study enrolling 26 patients. There were no significant differences between Prosigne and Botox regarding subjective global improvement, response onset, efficacy duration, and incidence and severity of adverse events. Our results suggest that Prosigne and Botox are comparable with respect to efficacy and safety for the short-term treatment of blepharospasm and hemifacial spasm.</abstract><cop>United States</cop><pmid>17272968</pmid><doi>10.1097/01.WNF.0000236771.77021.3C</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0362-5664 |
| ispartof | Clinical neuropharmacology, 2007-01, Vol.30 (1), p.39-42 |
| issn | 0362-5664 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20491970 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Blepharospasm - drug therapy Botulinum Toxins, Type A - pharmacology Cross-Over Studies Double-Blind Method Drugs, Chinese Herbal - pharmacology Female Hemifacial Spasm - drug therapy Humans Male Middle Aged Treatment Outcome |
| title | A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T12%3A27%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20double-blind,%20randomized,%20crossover%20study%20of%20prosigne%20versus%20botox%20in%20patients%20with%20blepharospasm%20and%20hemifacial%20spasm&rft.jtitle=Clinical%20neuropharmacology&rft.au=Rieder,%20Carlos%20R%20M&rft.date=2007-01-01&rft.volume=30&rft.issue=1&rft.spage=39&rft.epage=42&rft.pages=39-42&rft.issn=0362-5664&rft_id=info:doi/10.1097/01.WNF.0000236771.77021.3C&rft_dat=%3Cproquest_cross%3E20491970%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20491970&rft_id=info:pmid/17272968&rfr_iscdi=true |